Impax Laboratories — Merger or Acquisition (October 2017)
22 slides from Impax Laboratories's merger presentation, Oct 17, 2017
Slide 1: A Strategic Combination for Long-Term Growth
A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-
Slide 2: Additional Information and Forward Looking Statement
Additional Information and Forward Looking Statement Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitatio
Slide 3: Combining to Form a Stronger, More Diversified Pharmaceutical Company
Combining to Form a STRONGER, MORE DIVERSIFIED Pharmaceutical Company +
Slide 4: This is Amneal
amneal PHARMACEUTICALS This is Amneal
Slide 5: Amneal at a glance
$1.0B Revenue ~5,100 Colleagues 5th Largest U.S. Generics Company 15 Years of Growth and Achievement Headquartered in Bridgewater, NJ, USA
Slide 6: Complementary Culture and Values
Complementary Culture and Values Treat the world as our family There is a strong sense of family values, treating each other with respect and encouraging the very best in everyone Quality in everything we do Each employee at Amneal is a steward of quality Entrepreneurial spirit Innovation is in the
Slide 7: Diverse Generic Product Families
92 Diverse Generic Product Families PORTFOLIO PIPELINE 298 Products Filed or In Development 2 Biosimilars Opportunities PIPELINE
Slide 8: Strong In-House Manufacturing and R&D
R&D co-located within 7 facilities STRONG IN-HOUSE MANUFACTURING AND R&D BROOKHAVEN & HAUPPAUGE, NY PISCATAWAY, NJ PISCATAWAY, NJ & CASHEL, IRELAND AHMEDABAD & HYDERABAD, INDIA VIZAG & DEHEJ, INDIA PISCATAWAY, NJ LIQUID / TOPICAL TRANSDERMAL RESPIRATORY STERILE / ASEPTIC / SOD API U.S. AND EUROPE SO
Slide 9: Our Combined Company
Our Combined Company +
Slide 10: Well-Positioned for Long-Term Growth
Well-Positioned for Long-Term Growth Creates specialty pharmaceutical company with 5th largest U.S. generics business; growing high-margin specialty franchise Increases scale and diversification across currently marketed product families and R&D pipeline Expected Double-digit revenue and adjusted ea
Slide 11: Amneal + Impax at-a-glance
Amneal + Impax at-a-glance DOUBLE-DIGIT Revenue and Adjusted Earnings Growth INCREASED Scale and Diversification ~6,500 Colleagues ~10% of Combined Revenues Expected Annual R&D Investment ~165 Marketed Generic Product Families ~315 Projects in Industry-Leading Pipeline 2 Biosimilars Opportunities GR
Slide 12: Deepens U.S. Generics Business
Deepens U.S. Generics Business Expands generic portfolio to ~165 marketed product families All dosage forms: orals, injectables, topicals, transdermals, inhalation and devices Internal API capability Entry into biosimilars with one product filed and one near-term opportunity Source: IMS Health. (1)
Slide 13: Creates Robust Generics Pipeline
Creates Robust Generics Pipeline ~315 total projects ~165 R&D Projects ~150 Filed Projects Diversified, high-value pipeline ~50% potential exclusive First-to-File, First-to-File, First-to Market or other high-value opportunities DEVELOPMENT PIPELINE ~165 PROJECTS FILINGS ~150 ANDAS 14% 37% 14% 7% 15
Slide 14: Growing Specialty Pharma Business
Growing Specialty Pharma Business Differentiated medicines in core therapeutic categories: Central Nervous System Anti-Parasitic Infections Other Specialty Areas Growing marketed product portfolio: 116 specialty sales representatives covering neurologists and high-prescribing PCPs Provides stable ca
Slide 15: Comprehensive Suite of Dosage Form Capabilities
Comprehensive Suite of Dosage Form Capabilities IR / ER Solids Injectables Oral Liquids Nasal Sprays Respiratory Ophthalmics Patches Dermatology ü ü ü ü ü ü ü ü ü ü ü PARTNER ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü PARTNER ü ü ü ü ü ü ü ü PARTNER PARTNER û ü û ü ü ü PARTNER ü û ü ü PARTNER ü PARTNER û PARTNER
Slide 16: Increased Commitment to R&D; Diverse Manufacturing Capabilities
Increased Commitment to R&D; Diverse and Expansive Manufacturing Technology Capabilities Enhanced R&D capability aligned with manufacturing network Expected Annual R&D Investment: 10% of Combined Revenues INDIA LIQUID / TOPICAL TRANSDERMAL RESPIRATORY STERILE / ASEPTIC / SOD API HAYWARD, CA & BROOKH
Slide 17: Strong and Proven Employee and Leadership Team
Strong and Proven Employee and Leadership Team ~6,500 combined employees Amneal Pharmaceuticals, Inc. will be a public company Headquarters in Bridgewater, New Jersey Combined Leadership Chirag and Chintu Patel, co-Chairman, Board of Directors Paul Bisaro, CEO Bryan Reasons, CFO Combined management
Slide 18: United Under One Name: Amneal Pharmaceuticals
United Under One Name: Amneal Pharmaceuticals Reflects our strengthened characteristics Symbolizes our important work – providing high-quality medicines that improve the lives of individuals and families Represents our internal focus on fostering family values and entrepreneurial spirit Reflects our
Slide 19: Next Steps
Next Steps
Slide 20: Anticipated Timeline
Announcement Regulatory requirements Impax Shareholder meeting Close 1 2 3 4 Today 1H 2018 Anticipated Timeline Business as Usual until close Continue to focus on our day to day activities and priorities Pre-integration planning activities
Slide 21: Commitment to Communications
Commitment to Communications Committed to transparent, ongoing communications Memos Videos Town Halls iNET and Web Site Updates Pre-integration Newsletters We want to hear your questions and concerns Email [email protected] Speak with your manager or HR business partner
Slide 22: A Strategic Combination for Long-Term Growth
A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 +
Impax Laboratories — Merger or Acquisition (October 2017) on 6ix